MedTrace Logo

Use of Narrative Voice and Introduction Content to Improve Interactive Voice Response Surveys in Bangladesh and Uganda

NCT03772431 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5580

Last updated 2023-05-10

No results posted yet for this study

Summary

This study evaluates the effect of two different narrative voices (one male and one female) and two different introductions (one with informational content and the other with additional motivational content) on interactive voice response (IVR) survey cooperation, response, refusal, and contact rates, as compared to a control group (male, informational), in Bangladesh and Uganda.

Conditions

  • Surveys and Questionnaires
  • Noncommunicable Diseases

Interventions

OTHER

Female Voice

The survey was narrated by a female voice

OTHER

Motivational Introduction

The survey introduction was worded to include motivational content

OTHER

Male Voice

The survey was narrated by a male voice

OTHER

Informational Introduction

The survey introduction was worded to include informational content

Sponsors & Collaborators

  • The Bloomberg Family Foundation, Inc.

    collaborator OTHER

  • Makerere University

    collaborator OTHER

  • Institute of Epidemiology, Disease Control and Research

    collaborator OTHER

  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Principal Investigators

  • Adnan A Hyder, PhD, MBBS · Johns Hopkins University Bloomberg School of Public Health

  • George W. Pariyo, PhD · Johns Hopkins University Bloomberg School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-26
Primary Completion
2017-07-17
Completion
2017-07-17

Countries

  • Bangladesh
  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03772431 on ClinicalTrials.gov